Nicolas Kiavué

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

François‐Clément Bidard, William Jacot, Nicolas Kiavué et al. · JAMA Oncology · 2020 · 178 citations · Full text

Medicine, Oncology, Chemotherapy +16

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

François‐Clément Bidard, Nicolas Kiavué, Marc Ychou et al. · Cells · 2019 · 115 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

Luc Cabel, Frédérique Berger, Paul Cottu et al. · British Journal of Cancer · 2021 · 59 citations · Full text

Medicine, Oncology, Breast Oncology +15

Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial

François‐Clément Bidard, Nicolas Kiavué, William Jacot et al. · Journal of Clinical Oncology · 2023 · 47 citations

Medicine, Oncology, Breast Oncology +14

Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases

Alexandre De Moura, Delphine Loirat, Sinen Korbi et al. · Breast Cancer · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +17